Omics-Based Clinical Trials Industry Outlook 2025-2029: Market Set to Cross $44.08 Billion Milestone

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Omics-Based Clinical Trials Market Size By 2025?
The market size of omics-based clinical trials has seen robust growth in the past years. The market, which is set to expand from $29.10 billion in 2024 to $31.71 billion in 2025, is expected to witness a compound annual growth rate (CAGR) of 8.9%. This significant exponential growth in the past can be attributed to factors such as an increased number of clinical trials utilizing omics technologies, increased focus on translational research, enhanced government backing and funding, more accessible biobanks and biospecimens, and heightened awareness of the advantages of precision therapies.

How Big Is the Omics-Based Clinical Trials Market Size Expected to Grow by 2029?
Anticipated robust growth is on the horizon for the omics-based clinical trials market over the coming years, culminating in a valuation of $44.08 billion in 2029, signifying a compound annual growth rate (CAGR) of 8.6%. This market expansion predicted for the upcoming period is driven by factors such as the growing preference for personalized medicine, increased acceptance of multi-omics methods, a higher incidence of chronic and rare diseases, escalated investment in genomic research and biotechnologies, as well as a heightened emphasis on biomarker discovery. Noteworthy trends projected during this forecast period involve progress in next-generation sequencing (NGS) technologies, the blend of artificial intelligence with omics platforms, technical progress in bioinformatics tools, advancements in proteomics and metabolomics platforms, in addition to the amalgamation of multi-omics data.

View the full report here:
https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report

Which Key Market Drivers Powering Omics-Based Clinical Trials Market Expansion and Growth?
The surge in the desire for tailor-made healthcare is predicted to fuel the expansion of the omics-based clinical trials market. This medical practice, known as personalized medicine, customizes disease prevention, diagnosis, and treatment, basing it on each patient's unique traits. Rapid advancements in genomic technologies, which allow economical, swift analysis of individual genetic profiles, have led to an increased demand for personalized medicine. Omics-based clinical trials facilitate this type of medicine by identifying unique genetic, proteomic, and metabolic profiles, hence paving the way for treatment strategies that are more precise and effective for each patient. To illustrate, the Personalized Medicine Coalition, a professional membership organization based in the US, stated in February 2023 that the approval of 12 new personalized medicines in 2022 accounted for roughly 34% of all new therapies, reflecting a significant rise from the past years. As such, the escalating demand for personalized medicine is promoting the growth of the omics-based clinical trials market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp

What Are the Key Trends Driving Omics-Based Clinical Trials Market Growth?
Prominent firms in the omics-based clinical trials market are emphasizing the development of groundbreaking solutions like HiFi sequencing technology, aiming to boost the precision, velocity, and depth of multi-omics data analysis which, in turn, enhances trial results and individualized therapy approaches. HiFi sequencing signifies a revolutionary sequencing (NGS) tool that delivers long, extremely accurate reads through circular consensus sequencing (CCS). This allows for thorough and precise examination of genomes, transcriptomes, and epigenomes. For example, Pacific Biosciences of California Inc., a biotech firm based in the US, partnered with the Agency for Science, Technology, and Research (A*STAR) - a Singapore-based research and product development agency, and Macrogen Inc., a biotech company from South Korea, to open an advanced lab in Singapore in October 2024. The lab leverages pioneering long-read sequencing technology to expedite genomic innovation. It empowers researchers to undertake sophisticated genomic research with higher accuracy and rapidity, supporting numerous applications such as whole genome sequencing, transcriptomics, epigenetics, and metagenomics. Additionally, the lab cultivates partnerships among international scientists and local agencies with the aim of fast-tracking advancements in personalized medicine, diagnostics for rare illnesses, and pinpoint oncology. The lab also provides training initiatives and offers collective access to high-throughput sequencing infrastructure, thereby strengthening capacity and innovation in the Asia-Pacific area.

What Are the Emerging Segments in the Omics-Based Clinical Trials Market?
The omics-based clinical trials market covered in this report is segmented

1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics
2) By Phase: Phase I, Phase II, Phase III, Phase IV
3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders
5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories

Subsegments:
1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing
2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping
3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis
4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27369&type=smp

Who Are the Global Leaders in the Omics-Based Clinical Trials Market?
Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, and BioAro Inc.

Which are the Top Profitable Regional Markets for the Omics-Based Clinical Trials Industry?
North America was the largest region in the omics-based clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27369

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.